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Purpose: Preclinical ﬁndings suggest that adding targeted therapies to combination
radiation-chemotherapy can enhance treatment efﬁcacy; however, this approach may
enhance normal tissue toxicity.We investigated themaximum tolerated dose, dose-limiting
toxicities, and response rate when the selective cyclooxygenase-2 inhibitor celecoxib is
added to concurrent irinotecan, cisplatin, and radiation therapy for patients with inoper-
able stage II–III non-small cell lung cancer (NSCLC). Methods and Materials: Eighteen
patients were analyzed in a phase I clinical dose-escalation trial. Celecoxib was given daily
beginning 5 days before radiation followed by maintenance doses for 12weeks. Toxicity
was graded with the CommonTerminology Criteria for Adverse Events V3.0 and response
with the World Health Organization system. Primary endpoints were maximum tolerated
dose of celecoxib and treatment toxicity; secondary endpoints were response and survival
rates. Results:The maximum tolerated dose of celecoxib was not reached, in part owing
to discontinuation of the drug supply. At doses of 200 or 400mg/day, no patients experi-
enced any dose-limiting toxicity (acute grade ≥4 esophagitis or pneumonitis, neutropenic
fever or thrombocytopenia requiring transfusion, or acute grade ≥3 diarrhea). Grade 3 tox-
icities were leukopenia (ﬁve patients), fatigue (3), pneumonitis (2), dyspnea (1), pain (1),
and esophageal stricture (1). Interestingly, pulmonary ﬁbrosis (a late toxicity) was no more
severe in the higher-dose (400-mg) group and may have been less common than in the
lower-dose group. The clinical response rate was 100% (8 complete, 10 partial). Two-year
rates were: overall survival 65%; local-regional control 69%; distant metastasis-free sur-
vival 71%; and disease-free survival 64%. Conclusion: Although preliminary, our results
suggest that adding celecoxib to concurrent chemoradiation for inoperable NSCLC is safe
and can improve outcome without increasing normal tissue toxicity.
Keywords: celebrex, CPT-11, cyclooxygenase-2 inhibitor, concurrent chemoradiotherapy, stage II or III non-small cell
lung cancer
INTRODUCTION
Lung cancer is a major cause of cancer-related mortality world-
wide (Jemal et al., 2011), with 5-year survival rates of only about
16%. Roughly one-third of non-small cell lung cancer (NSCLC)
presents as locally advanced disease, with tumor or nodal involve-
ment of the mediastinum. Because disease at this stage is often
not resectable, deﬁnitive treatment that combines platinum-based
chemotherapy and radiation therapy is considered the standard of
care (Furuse et al., 1999; Pﬁster et al., 2004; Blackstock and Govin-
dan, 2007), particularly for patients with good performance status.
However, the optimal schedule and components of chemoradio-
therapy regimens are still being explored, and the 5-year survival
rates still leave considerable room for improvement.
Concurrent chemoradiation seems to be more effective than
sequential therapy, as demonstrated by the West Japan Lung
Group (Furuse et al., 1999), the Radiation Therapy Oncology
Group (RTOG) in trial 94-10 (Curran et al., 2011), and the
French NPC-9501 trial (Fournel et al., 2005). However, these tri-
als used older chemotherapy agents (e.g., vindesine, vinblastine,
etoposide),whereasmore recent regimens that combine platinum-
based chemotherapy with other agents (e.g., docetaxel, paclitaxel,
irinotecan, gemcitabine, vinorelbine) seem to be more effective
for advanced NSCLC (Kubota et al., 2004; Baggstrom et al., 2007).
However, the newer chemotherapy agents must be administered
in reduced doses in combination with thoracic radiation therapy
to avoid producing unacceptable toxicity.
One such agent being studied in combination with platinum-
based chemotherapy and radiation is irinotecan (CPT-11), a topoi-
somerase I inhibitor with radiosensitizing effects (Tamura et al.,
1997). Irinotecan is thought to have synergistic effects with cis-
platin in NSCLC (Yamada et al., 2002; Takiguchi et al., 2005; Kim
et al., 2006). Several trials of irinotecan, cisplatin, and radiation
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for locally advanced NSCLC (Takiguchi et al., 2005; Langer et al.,
2007) have shown that this combination has promise but is limited
by both acute toxicity, particularly esophagitis and pneumonitis,
and late toxicity, mostly diarrhea. These effects may be related to
increases in tissue prostaglandin E2 (PGE2) levels; Trifan et al.
(2002) reported that both cyclooxygenase-2 (COX-2) and PGE2
protein levels were increased after irinotecan in mouse and rat
models and that the selective COX-2 inhibitor celecoxib enhanced
the antitumor effect while blunting late diarrhea in these mod-
els. Overexpression of COX-2 in lung cancer is associated with
aggressive tumor growth, facilitation of metastatic spread, and
poor patient survival (Achiwa et al., 1999; Khuri et al., 2001;
Liao et al., 2005). If inhibiting this enzyme with COX-2 inhibitors
can enhance tumor radioresponse without appreciably increasing
radiation-induced normal tissue damage, then COX-2 inhibitors
could increase the therapeutic ratio of radiation therapy (Komaki
et al., 2004).
We hypothesized that combining celecoxib with irinotecan,
cisplatin, and radiation therapy would have the dual beneﬁt of
enhancing antitumor effects and reducing toxicity and thus could
improve outcome for patients with unresectable NSCLC. We
describe here the ﬁndings from a phase I study of a novel regi-
men combining celecoxib with irinotecan, cisplatin, and radiation
therapy for patients with unresectable stage II–III NSCLC.
MATERIALS AND METHODS
This phase I prospective clinical trial was approved by the appro-
priate institutional review board of The University of Texas
MD Anderson Cancer Center, and all patients provided writ-
ten informed consent before participating. A total of 20 patients
with inoperable stage II or III NSCLC were enrolled beginning in
November 2003. Inoperability,whethermedical or disease-related,
was determined jointly by a group of thoracic surgeons, thoracic
radiation oncologists, and medical thoracic oncologists at MD
Anderson. In most cases, stage II or IIIA disease was inoperable
for medical reasons and stage IIIB disease was inoperable owing
to tumor proximity to critical structures.
ELIGIBILITY CRITERIA
Inclusion criteria were as follows: histologic or cytologic evidence
of NSCLC; unresectable stage II or III disease; good performance
status (Karnofsky score ≥70); age 18–70 years; no prior radia-
tion or combined-modality therapy for other malignancy; no
evidence of distant metastatic disease; and adequate end-organ
indices [i.e., absolute neutrophil count ≥2,000/μL, platelet count
≥100,000/μL, serum creatinine level ≤1.5 mg/dL, total bilirubin
≤1.5× institutional upper limit of normal (1.0 IU/L), and aspar-
tate aminotransferase levels ≤1.5× institutional upper limit of
normal (46 IU/L)]. Prior chemotherapy was allowed if it had been
completed at least 4 weeks before study entry. Use of low-dose
aspirin (<200 mg/day) was allowed, but regular use of high-
dose aspirin (>2 g/day) or other non-steroidal anti-inﬂammatory
drugs was not.
Exclusion criteria were history of gastric ulcer, gastrointestinal
bleeding, or renal failure; history of poorly controlled hyperten-
sion (systolic >150 mmHg), angina, or other cardiac abnormali-
ties; history of cardiovascular disease (e.g., myocardial infarction,
angina, coronary angioplasty, congestive heart failure, stroke, or
coronary bypass surgery in the past 6 months); family history
of premature coronary disease (i.e., onset <55 years); receipt
of amifostine within the past 6 months; history of active, inva-
sive malignancies curatively treated in the past 2 years; aller-
gies to sulfonamides, non-steroidal anti-inﬂammatory drugs, or
celecoxib; uncontrolled hypercholesteremia (low-density lipopro-
tein cholesterol levels of >200 mg/dL more than twice in
repeated tests); history of deep venous thrombosis, pulmonary
embolism, or systemic lupus erythematosus; family history of
protein S or C deﬁciencies; and prior heparin-induced throm-
bocytopenia, factor V Leiden deﬁciencies, or high homocysteine
levels.
ENDPOINT, DOSE ESCALATION, AND DOSE-LIMITING TOXICITY
The phase I endpoint (the maximum tolerated dose of celecoxib
combined with ﬁxed-dose irinotecan and cisplatin plus radiation)
was to be determined by standard dose escalation in 10-patient
cohorts. Ten patients were to be entered at each dose level begin-
ning at 200 mg/day. Enrollment in the higher-dose groups was
to be terminated of ≥5 patients had grade ≥3 esophagitis or
pneumonitis. If ≤4 patients showed grade≥3 esophagitis or pneu-
monitis, 10 patients were to be entered at the next higher-dose
level.
Adverse events were deﬁned according to the Common Termi-
nology Criteria for Adverse Events v3.0 (National Cancer Institute,
2006). Dose-limiting toxicities were acute neutropenic fever (tem-
perature >100.6˚F with absolute neutrophil count <1,000/μL);
acute thrombocytopenia requiring transfusion; acute grade ≥4
esophagitis or pneumonitis; acute grade ≥3 diarrhea; and any
treatment-related grade 5 toxicity. The maximum tolerated dose
was deﬁned as 1 dose level below that causing any dose-limiting
toxicity.
TREATMENT
The treatment schema is shown in Figure 1. Radiation therapy was
started after 5 days of celecoxib and given in 1.8-Gy daily fractions,
5 fractions/week, for 7 weeks (total dose 63 Gy in 35 fractions).
The gross tumor volume included the complete extent of visible
primary tumor and lymph nodes visualized on radiography. Clin-
ical target volume encompassed the gross tumor volume plus a
margin of 8 mm, and the planning target volume encompassed
the clinical target volume plus a margin of at least 7 mm but no
more than 13 mm. The supraclavicular fossa was not included in
the treatment ﬁeld unless the primary tumor was located in the
upper lobe or a supraclavicular node was clinically involved. The
ipsilateral hilar lymph nodes (with a 1.5-cm margin) and the con-
tralateral hilar lymph nodes (with a 1-cm margin) were routinely
included in the radiation ﬁelds. Three-dimensional conformal or
intensity-modulated radiotherapy treatment planning was used
in all cases, and radiation doses were prescribed to an isodose line
covering 95% of the planning target volume with no lung hetero-
geneity correction. The radiation beam energy was deﬁned by the
optimized treatment plan.
Irinotecan was administered once a week for 7 weeks (on day
1 of weeks 2–8) at 30 mg/m2 as a 90-min intravenous infusion
before the cisplatin. Cisplatin was administered once a week for
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7 weeks (weeks 2–8) at 25 mg/m2 as a 60-min intravenous infusion.
Hydration included at least 1 L of intravenous ﬂuids before the cis-
platin infusion,plus at least 1 additional liter of ﬂuidwithmannitol
and appropriate electrolytes afterward. Celecoxib was given orally
[10 patients at 200 mg/day and 10 at 400 mg/day (200 mg, twice-
daily)] beginning 5 days before the chemoradiation; the same dose
was continued throughout the 8-week course of chemoradiation
therapy and for four more weeks thereafter (through week 12).
BASELINE AND FOLLOW-UP EVALUATIONS
Baseline evaluations included complete medical history and phys-
ical examination, with documentation of Karnofsky performance
status, recent weight loss, usual weight, and concurrent non-
malignant diseases and therapies. Laboratory studies were done
before registration and included complete blood counts; blood
chemistries; alanine aminotransferase levels; and urinalysis. Imag-
ing studies were to be obtained within 6 weeks before study reg-
istration and included chest X-ray, computed tomography (CT)
of the chest (including upper abdomen), magnetic resonance
imaging of the brain,positron emission tomography, and radionu-
clide bone scanning as needed. Patients suspected of having gas-
trointestinal bleeding underwent esophagogastroduodenoscopy.
All patients underwent pulmonary function tests and electrocar-
diography before treatment. The location, type, and size of all
measurable lesions were documented before treatment.
Patients were assessed weekly during radiation therapy, with
interval history and physical examinations, with particular atten-
tion to drug-induced side effects and changes in body weight and
performance status; laboratory tests were also performed weekly.
Blood chemistrywas assessed as needed to deﬁne drug toxicity, and
esophagogastroduodenoscopy was used when clinically indicated.
Tumor measurements, response of each lesion, site, and overall
response were documented before and 1 month after the entire
course of therapy had been completed. Patients were required to
ﬁll out medication diaries to assess compliance.
RESPONSE CRITERIA
Tumor response was evaluated according toWorld Health Organi-
zation criteria (Miller et al., 1981), inwhich tumorsweremeasured
in two dimensions on chest X-rays, CT scans, or sonograms and
their area estimated as the product of the longest diameter and its
perpendicular dimension. Complete response was the disappear-
ance of all clinical evidence of tumor that persisted for at least
4 weeks; partial response as a decrease in the sum of the areas of
all measured lesions of >50% that persisted for at least 4 weeks.
Regression of lesions not fulﬁlling the criteria of partial response
but without evidence of progression was considered stable disease.
Progressive disease was any increase exceeding 25% in the areas of
any measurable lesion or the appearance of new lesions (includ-
ing brain lesions). Response durations were measured from the
time of response (not the beginning of treatment) until evidence
of progressive disease appeared. Survival duration was measured
from the day of registration to the date of last follow-up or doc-
umented death. Patterns of failure were assessed from the day of
registration to the date of the ﬁrst documented failure.
STATISTICAL METHODS
Pearson’s chi-square tests were used to assess associations between
acute normal tissue toxicity or late normal tissue toxicity and
celecoxib dose in frequency tables. Overall survival was measured
from the date of NSCLC diagnosis to the date of last follow-up or
documented death. Kaplan–Meier survival estimates were used to
calculate survival distributions and log-rank tests to assess quality
of survival function. P values≤ 0.05 were considered to indicate
statistically signiﬁcant differences for all two-sided statistical tests.
All analyses were done with Stata statistical software (Release 10,
2007; StataCorp LP, College Station, TX, USA).
RESULTS
Twenty patients with unresectable NSCLC (2 stage II and 17 stage
III) were enrolled over a 4-year period. Themedian follow-up time
was 25.3 months (range, 7.0–60.4 months). Two patients [both in
the lower-dose (200 mg) celecoxib group]withdrew from the study
after the ﬁrst weekly dose of irinotecan, one after experiencing an
abdominal rash that spread to both breasts and thighs and the
other after severe chest pain, nausea, and vomiting requiring inpa-
tient intravenous rehydration. The other 18 patients completed
the protocol treatment and were eligible for analysis. The trial was
stopped early in September 2008 because of slow accrual owing to
publication of three randomized trials demonstrating increased
FIGURE 1 |Treatment schema. Radiation therapy was started after 5 days of
celecoxib. Cisplatin and irinotecan were administered once a week for
7weeks (weeks 2–8). Celecoxib was given orally beginning 5 days before the
initiation of chemoradiation therapy; the same dose was continued daily
throughout the entire 8-week course of chemoradiation therapy and for four
more weeks thereafter (through week 12).
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cardiac toxicity from another selective COX-2 inhibitor, rofecoxib
(Vioxx), and the withdrawal of that drug from the market. As a
result, no patients were enrolled in a planned 800-mg dose group
(the maximum allowable dose according to the U.S. Food and
Drug Administration). Characteristics of the 18 eligible patients
are shown in Table 1. The median patient age was 62 years (range,
42–74 years); 4 (22%) had adenocarcinomas, 11 (61%) squamous
cell carcinomas, and 3 (17%) unspeciﬁed NSCLC.
TOXICITY
Eighteen patients were evaluable for toxic effects (Table 2). Pul-
monary toxicity was diagnosed by thoracic radiologists who were
blinded as to treatment group, and the diagnosis was subsequently
conﬁrmed by radiation oncologists with the isodose curves. No
patient experienced grade 4 toxicity or dose-limiting toxicity;
hence the maximum tolerated dose was not reached. No patient
experienced grade ≥3 treatment-related esophagitis; two patients
(11%) had grade 3 pneumonitis. No differences in these toxic
effects were noted between celecoxib dose groups (P> 0.05). Sim-
ilarly, the incidence of grade 3 leukopeniawas no different between
groups (three in the 200-mg group and two in the 400-mg group,
P = 0.25). However, pulmonary ﬁbrosis (assessed on chest CT
scans and diagnostic image reports) was worse in the lower-dose
group [one grade 0 and seven grade 1 in the 200-mg group vs. six
grade 0 and four grade 1 in the 400-mg group (P = 0.04)].
EFFICACY
Tumor response, although not the primary endpoint, was evalu-
able in 18 patients: 7 had complete response and 11 had partial
response of the primary lung tumor; 9 patients had complete
response and9partial response of nodal lymphadenopathy.Tumor
response rateswerenot signiﬁcantly different between the twodose
groups (P > 0.05).
TUMOR CONTROL AND SURVIVAL
Treatment outcomes are shown in Figure 2. The median over-
all survival time for all 18 patients was 37.5 months (range,
7.0–60.4 months). At 2 years, rates for all 18 patients were as
follows: overall survival 65%; local-regional control 69%; dis-
tant metastasis-free survival 71%; and disease-free survival 64%.
Patients in the two celecoxib dose groups did not differ in median
overall survival time (37.5 months for the 200-mg group vs.
50.9 months for the 400-mg group, P> 0.05), 2-year overall sur-
vival rate (75% for 200 mg vs. 58% for 400 mg, P> 0.05), local-
regional control rate (71% 200 mg vs. 70% 400 mg, P > 0.05),
distant metastasis-free survival rate (86% 200 mg vs. 60% 400 mg,
P> 0.05), or disease-free survival rate (71% 200 mg vs. 60%
400 mg, P> 0.05).
DISCUSSION
The combination of radiation and chemotherapy for lung cancer
has been shown to improve tumor response rates (84% for concur-
rent chemoradiation therapy vs. 66% for radiation alone; Furuse
et al., 1999), 3-year survival rates (29.7% for weekly paclitaxel vs.
16.8% for radiation alone; Huber et al., 2006), and 5-year sur-
vival rates (8.2% for concurrent chemoradiation therapy vs. 6.0%
for radiation alone; Auperin et al., 2006). Preclinical ﬁndings sug-
gest that molecular targeted therapies can enhance efﬁcacy when
used in combination with other treatment modalities; however,
whether such therapies would enhance normal tissue toxicity has
been unclear.
The primary goal of this phase I study was to determine the
maximum tolerated dose of celecoxib given in combination with
irinotecan, cisplatin, and thoracic radiation; secondary goals were
to determine the feasibility of this therapy in terms of its toxic-
ity proﬁle and its effectiveness. We found that celecoxib can be
safely administered in doses up to 400 mg in this combination for
Table 2 | Acute and late toxic effects of patients given 200 or 400mg celecoxib with chemoradiation therapy for non-small cell lung cancer.
Toxic effect Celecoxib dose group P value
Toxicity grade 200mg/day Toxicity grade 400mg/day
0 1 2 3 4 0 1 2 3 4
Pneumonitis 0 5 4 1 0 1 7 1 1 0 0.69
Esophagitis 0 1 7 0 0 2 3 5 0 0 0.21
Radiation dermatitis 0 4 4 0 0 1 5 4 0 0 0.64
Pericardial effusion 7 1 0 0 0 10 0 0 0 0 0.31
Fatigue 0 2 6 0 0 2 0 6 2 0 0.12
Dyspnea 5 2 0 1 0 9 0 1 0 0 0.17
Pain 4 1 2 1 0 9 0 1 0 0 0.09
Nausea 4 3 1 0 0 6 3 1 0 0 0.91
Pulmonary ﬁbrosis 1 7 0 0 0 6 4 0 0 0 0.04
Esophageal stricture 8 0 0 0 0 8 1 0 1 0 0.41
Anemia 3 4 1 0 0 5 3 1 1 0 0.67
Leukopenia 4 1 0 3 0 5 0 3 2 0 0.25
Thrombocytopenia 7 1 0 0 0 7 1 2 0 0 0.41
Bold indicates that the P value is less than 0.05.
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FIGURE 2 |Treatment outcomes for 18 eligible patients. Survival duration was measured from the day of registration to the date of last follow-up or
documented death. Failure was measured from the day of registration to the date of ﬁrst documented failure event.
patientswithunresectable stage II or IIINSCLC.Nopatients devel-
oped treatment-related cardiac problems,diarrhea,or neutropenic
fever. No patients developed treatment-related grade ≥3 acute
thrombocytopenia or anemia requiring transfusion. One patient
in each celecoxib dose group (200 or 400 mg/day) developed grade
3 pneumonitis, which could have resulted from the radiation, the
drug therapy,or both.Nopatients experienced any grade 4 toxicity.
The most common grade 3 toxicity was leukopenia (three patients
in the low-dose group and two in the higher-dose group), but this
could also be attributable to concurrent chemotherapy. Hence we
found no evidence of increased normal tissue toxicity from the
addition of celecoxib – indeed, esophagitis and pneumonitis were
no worse in the higher-dose (400 mg) group. The apparent differ-
ence in lung ﬁbrosis between groups, with the lower-dose group
experiencing more ﬁbrosis, needs to be veriﬁed in a larger-scale
phase II or III trial. Nevertheless, these ﬁndings compare quite
favorably with results of a phase II study indicating no improve-
ment in side effects from the addition of celecoxib to second-line
therapy (Lilenbaum et al., 2006).
The response rates in this study (44% complete, 56% partial)
were higher than those in studies by Mutter et al. (2009; 7% com-
plete and 36% partial) and Altorki et al. (2003; 17% complete and
48% partial).We are reluctant to speculate as to why this is the case
given the very small number of patients in our study and the fact
that tumor response was not a primary endpoint. However, our
chemotherapy regimen (cisplatin and irinotecan) was different
that that of these other studies (carboplatin and paclitaxel), and
patients in these other studies may have had bulkier tumors or
poorer performance status than ours did. We further recognize
that tumor response is more commonly assessed with RECIST
than with the WHO criteria, which was the institutional policy at
the time; however, our response rates would have been still higher
if we had used the RECIST system. Moreover, the 2-year overall
survival rate in our study, 69%, was also excellent compared with
other trials of combined chemoradiotherapy such as RTOG 9801
(Movsas et al., 2005) and RTOG 94-10 (Curran et al., 2011).
We conclude that adding celecoxib to weekly irinotecan and
cisplatin with concurrent thoracic radiation therapy for unre-
sectable stage IIB or III NSCLC is safe, feasible, and may improve
outcomes. Further randomized phase II trials are needed to deter-
mine the clinical signiﬁcance of celecoxib and pulmonary ﬁbrosis,
and a prospective randomized phase III trial is needed to deﬁni-
tively determine if adding a COX-2 inhibitor such as celecoxib to
chemoradiation therapywill produce a survival beneﬁt for patients
with unresectable stage IIB or III NSCLC.
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